Antimicrobial Stewardship

A paradigm shift is emerging when it comes to the clinical approach to prescribing antibiotics. One clinician weighs in on using this class of therapeutics more judiciously.

By addressing ART-related medication errors and increasing linkage to care, antiretroviral stewardship programs can improve management of inpatients with HIV.

This was the first study to compare clinical outcomes in carbapenemase-producing (CP-CRE) and non–carbapenemase-producing (nCP-CRE) infections.

The FDA’s Antimicrobial Drugs Advisory Committee (AMDAC) voted 12-0 in favor of recommending this antibiotic and sets up a PDUFA target action date of May 29.

Several years after its FDA approval, this antibiotic continues to prove its efficacy in vitro across various pathogens related to these infections.

Alita Miller, PhD, senior vice president of research at Entasis Therapeutics, discusses positive trial data for Sulbactam-durlobactam (SUL-DUR) slated to be presented at ECCMID 2023.

Catch up with this week's 5 most-read infectious disease stories.

With limited amounts of antibacterials, prescribers are presented with optimal therapy challenges as well as difficulties in trying to achieve stewardship.

Reducing unnecessary antibiotic prescriptions for viral upper respiratory tract infections is crucial to stop the spread of antimicrobial resistance.

The investigators compared sources of antibiotic resistant genes in human, animal, soil, water/sediment, and wastewater treatment plants.

Increased sales of these antibiotics during the COVID-19 pandemic raise concerns about the growing threat of antimicrobial resistance.

"Antibiotics can safely be withheld in most patients with viral respiratory infections,” these study authors wrote.

This week's hottest topics included the risks of proton pump inhibitors, rare tickborne disease, HIV vaccination, COVID-19 immunity from a common cold, and hydrocortisone for pneumonia.

A food for thought as an ambulatory antibiotic stewardship initiative.

Candida auris fungal infections increased 95% in 2021, and drug-resistant cases are continuing to spread across the US.

A study demonstrated patients were frequently prescribed broad-spectrum antibiotics when more narrowly tailored antibiotics were considered the optimal choice.

A third to a half of PPIs are overprescribed, potentially leading to an increased risk of the colonization with drug-resistant microorganisms.

This study analyzed concerns that a lack of time may lead primary care physicians to prescribe unnecessarily as a “quick fix.”

The congressional bill has been on Capitol Hill for over 2 years now, and the interested stakeholders are continuing their lobbying efforts to get it passed.

Antimicrobial stewardship programs can protect drugs listed on the WHO Watch List, but the benefits are also dependent on countries' income level.

An increase in extensively drug-resistant Shigella infections prompted the CDC to release a health advisory for this major cause of bacterial diarrhea.

Although fecal microbiota, live-jslm (Rebyota; RBX2660) is the first fecal microbiota product approved by the FDA, there are other microbiota-based agents in the pipeline.

Both undertreatment and overtreatment were common in this cohort of penicillin-allergic pregnant women with Group B Streptococcus (GBS).

This study characterized the incidence of serotonin syndrome and identified contributing risk factors with combined medications for opioid use disorder (MOUD) and linezolid use.

Six respiratory infections are among the most common diagnoses for which antibiotics often are inappropriately prescribed, and new research sheds light on the effects, both in increased risk of adverse events and excess health care costs.

Antibiotics are apparently not the only widely used pharmaceuticals that can induce emergence of treatment resistant bacteria.

Looking to appeal to the financial incentives of antibiotic development, a recent policy paper explores how lives can be saved and a return of investment (ROI) can be realized.

Patients treated with SER-109 reported a significant improvement in disease-specific health-related quality-of-life, regardless of their clinical outcome.

The investigational therapy developed by Entasis is indicated for treatment of Acinetobacter baumannii.